

## Subject Index for Volume 60

(ASHG) = ASHG communication; (E) = editorial; (L) = letter to the editor; (R) = review article

- Abnormalities, 474  
Aboriginal people, 1552 (L)  
Acrosin, 113  
Adaptor, 463 (L)  
Adenylate kinase, 133  
ADHD (attention-deficit hyperactivity disorder), 1276 (E)  
Admixture, 188, 241 (L), 957  
ADPKD (autosomal dominant polycystic kidney disease), 1399  
Affected relatives, 979  
Affected sib pair, 657  
    Analysis, 735 (L), 738 (L)  
African American, 1233 (L)  
African populations, 755 (E), 772  
Age at onset, 1079, 1202  
Age distribution of variants, 197  
AGG interspersions, 103  
Aging, 330, 948  
Allele(s)  
    Age, 447  
    Frequency, 197  
    Imbalance, 121  
    Sharing, 965  
Allelic association, 197  
Allelic imbalance, 121  
*Alu*, 808  
    Repeat, 798  
*Alu-Alu* recombination, 48  
Alzheimer disease, 205, 439, 948  
Ancient DNA, 1001 (L), 1002 (L)  
Androgen-insensitivity syndrome, 1003 (L)  
Androgen-receptor gene, 1003 (L)  
Anesthesiology, 1303 (E)  
Angelman syndrome, 144 (L), 574  
Angiotensinogen, 1448  
Anomalies, 474  
    Congenital, 1558 (L)  
Anticipation, 121, 630, 730 (L), 842, 1256 (L)  
Apolipoprotein, 638  
    E, 439, 948  
Arachnodactyly, 1389  
Arterial hypertension, 1448  
Ascertainment bias, 630  
ASHG Presidential Address, 1 (ASHG)  
ASHG report, 1265 (ASHG)  
Ashkenazic Jewish population, 505, 1085  
Asian lineages, 772  
Asian origins, 1174  
Asian populations, 755 (E)  
Association studies, 676  
AT/AT-V heterodimers, 1246 (L)  
Ataxia, spinocerebellar, 842  
Ataxia telangiectasia, 1246 (L), 1487  
    Variant, 605  
Attention-deficit hyperactivity disorder, 1276 (E)  
Atherosclerosis, 1552 (L)  
*ATP7A*, 63  
Attributable risk, 496  
Authentication, 1001 (L)  
Autism, 928, 1276 (E)  
Autosomal dominant, 1474  
    Hearing loss, 1168  
Autosomal recessive inheritance, 57  
AV conduction block, 891  
Azoospermia factor, 237 (L)  
  
Basal cell  
    Carcinoma, 10 (E)  
    Nevus syndrome, 10 (E)  
Basement membrane, 1344  
Bayesian, 625  
Beals syndrome, 1389  
Becker muscular dystrophy, 1555 (L)  
Behavior, 1289 (E)  
    Disorder, 1276 (E)  
Behavioral genetics, 13 (E), 1265 (ASHG)  
Belgian populations, 1041  
Berlin breakage syndrome, 605, 1246 (L)  
 $\beta$ -Globin, 1001 (L)  
    Gene polymorphisms, 772  
Bingo loci, 611  
Bipolar disorders, 730 (L), 1283 (E)  
Birth-death process, 447  
Bladder, 1461  
Blindness, 272 (E)  
Blistering skin diseases, 352, 1344  
Blood pressure, 1502  
Body fat, 166  
Bone, 790  
    Mass, 1309 (E), 1326  
Books reviewed, author(s)/editor(s):  
    Bérubé, M., 1567  
    Clark, D. P., 1568  
    Culver, K., 1566  
    Fujimura, J. H., 1258  
    Gardner, R. J. M., 1567  
    Hill, A., 744  
    Hubbard, R., 248  
    Kalousek, D. K., 744

- Keeling, J. W., 744  
 Lindee, M. S., 248  
 McGillivray, B., 744  
 Nelkin, D., 248  
 Norman, M. G., 744  
 Ponder, B. A. J., 743  
 Poskitt, K., 744  
 Russell, L. D., 1568  
 Silver, L. M., 1564  
 Sutherland, G. R., 1567  
 Wald, E., 248  
 Waring, M. J., 743  
 Weiss, K. M., 1565
- Books reviewed, title:  
*Chromosome Abnormalities and Genetic Counseling*, 2d ed., 1567  
*Congenital Malformations of the Brain: Pathological, Embryological, Clinical, Radiological, and Genetic Aspects*, 744  
*Crafting Science: A Sociohistory of the Quest for the Genetics of Cancer*, 1258  
*DNA Mystique: The Gene as a Cultural Icon*, The, 248  
*Exploding the Gene Myth*, 248  
*Fetal Pathology*, 1008  
*Gene Therapy: A Primer for Physicians*, 2d ed., 1566  
*Genetic Variation and Human Disease: Principles and Evolutionary Approaches*, 1565  
*Genetics of Cancer*, The, 743  
*Life as We Know It: A Father, a Family, and an Exceptional Child*, 1567  
*Molecular Biology Made Simple and Fun*, 1568  
*Mouse Genetics*, 1564
- Bottleneck, 408  
 Bottleneck theory, 1495  
 BP180, 1344  
 Brachydactyly, 732 (L)  
 Branch point, 1389  
 BRCA1, 313, 486, 496, 505, 1013 (E), 1021, 1031, 1041, 1059, 1068, 1233 (L), 1239 (L), 1242 (L)  
 Mutation(s), 496, 1085  
 BRCA2, 313, 486, 505, 1013 (E), 1031, 1050, 1059, 1068, 1079, 1236 (L), 1242 (L)  
 Mutation, 1085  
 Breakpoint junction, 574  
 Breast cancer, 313, 486, 496, 505, 1013 (E), 1021, 1031, 1041, 1050, 1059, 1079, 1085, 1233 (L), 1236 (L), 1239 (L), 1242 (L)  
 Familial, 1068  
 Male, 1068  
 British Isles, 388, 474  
 Bruton tyrosine kinase, 798
- C-propeptide, 547  
 C677T mutation, 999 (L)  
 CACLN1A3, 1316  
 CAG repeats, 730 (L), 842  
 CAG size, 1202  
 Calcium channel, 1316  
 Cancer, 469 (E), 486, 751 (E)  
 Breast, 313, 486, 496, 505, 1013 (E), 1021, 1031, 1041, 1050, 1059, 1068, 1079, 1085, 1233, 1236 (L), 1239 (L), 1242 (L)  
 Childhood, 474  
 Colorectal, 879, 910  
 Familial, 1256 (L)  
 Ovarian, 496, 505, 1021, 1041, 1068, 1085, 1233, 1239 (L), 1242 (L)  
 Pediatric, 1256 (L)  
 Syndromes, 233 (L)  
 Candidate genes, 1474  
 CANP3, 1128  
 Cardiomyopathy, 891  
 Cardiovascular syndrome, 143  
 Carotid body tumor, 121  
 Carrier detection, 581, 1003 (L), 1411  
 Carrier prevalence, 496  
 Carrier screening, 935  
 Caucasian, 381  
 cDNA selection, 574  
 Centenarians, 999 (L)  
 CFTR, 447  
 CGG repeat, 103  
 Charcot-Marie-Tooth disease, 230 (L)  
 Cholesterol, 1502  
 Chondrosarcoma, 80  
 Chorionic villus sampling, 917  
 Chromosome 1p, 1150  
 Chromosome 1q11-21, 891  
 Chromosome 3, 166, 296  
 Chromosome 3q13 locus, 525  
 Chromosome 4q, 1158  
 Chromosome 5, 515  
 Chromosome 6, 174, 588  
 Chromosome 6p, 27  
 Chromosome 7, 597  
 Chromosome 8, 330, 605  
 Chromosome 9, 133  
 Chromosome 11, 166, 1326  
 Chromosome 11p, 426  
 Chromosome 11q, 1168  
 Chromosome 11q23, 121  
 Chromosome 12p, 732 (L)  
 Chromosome 14, 1479  
 Chromosome 15p, 27  
 Chromosome 15q duplication, 928  
 Chromosome 17, 896  
 Chromosome 18, 860  
 Chromosome 18q<sup>-</sup> syndrome, 860  
 Chromosome 19, 617

- Chromosome 19q13.1, 611  
 Chromosome 21, 342  
 Chromosome 22q11 deletion, 851, 1544 (L)  
 Chromosome 22q13-qter, 57  
 Chromosome 22q13.3, 113  
 Chromosome X, 160, 581, 1139, 1312 (E), 1333, 1468  
   Inactivation, 581, 798, 903, 1312 (E), 1333, 1558 (L)  
   Linkage, 153  
     Diseases, 790, 910, 1468, 1542 (L)  
       Agammaglobulinemia, 798  
       Cardiomyopathy, 1555 (L)  
 Chromosome Xq27, 153  
 Chromosome Xq28, 903  
 Chromosome Y, 237 (L), 1174  
   DNA, 1174  
   Polymorphism, 241 (L)  
 Chromosome-instability syndromes, 1246 (L)  
 Chromosome mapping, 1487  
 Clubfoot, 426  
 CMT1A (Charcot-Marie-Tooth disease type 1A)  
   Duplication, 230 (L)  
   Prevalence, 230 (L)  
 Coalescence times, 772  
 Coalescent theory, 447  
 Cockayne syndrome, 320  
 Cognition, 13 (E)  
 Cognitive health, 948  
*COL5A1*, 547  
 Collagen  
   Biosynthesis, 48  
   Type XVII, 352, 1344  
 Colorectal cancer, 879, 910  
 Complementation assay, 1487  
 Complementation groups, 605  
 Complementation studies, 1246 (L)  
 Complex diseases, mapping, 1222  
 Complex phenotype, 27  
 Complex traits, 979  
 Compound heterozygote, 1251 (L), 1411  
 Concordant pairs, 1211  
 Cone dystrophy, 1468  
 Cone-rod dystrophy, 1562 (L)  
 Cone-shaped epiphyses, 732 (L)  
 Congenital anomalies, 469 (E), 851  
 Constrictive pericardium, 896  
 Contamination, 463 (L)  
 Contractural arachnodactyly, 818  
 Copper, 1423  
 Coronary disease, 228 (L), 1502  
 Cost effectiveness, 1211  
 Counseling, 40  
   Directive/nondirective, 17 (E)  
   Genetic, 17 (E)  
 CpG islands, 1139  
 Craniofacial development, 515  
 Craniosynostosis, 555  
 Cross-ethnic study, 703, 717  
 Cumulative risks, 496  
 Cystatin B, 342  
 Cystein substitution, 547  
 Cystic fibrosis, 87, 447, 935  
 Cystinuria, 611, 617  
 Cytochrome P450 2D6, 284  
 Cytogenetics, 581  
  
 D-loop, 153, 1363  
 D1S7, 417  
 D7S21, 417  
 D12S11, 417  
 D22S163, 113  
 Danish Populations, 1532 (L)  
 Database, 463 (L)  
 De novo mutation, 233 (L), 1003 (L)  
 De novo pyrimidine biosynthesis, 525  
 Deafness, hereditary, 758 (R)  
 Debrisoquine polymorphism, 284  
 del(17)(p11.2), 1184  
 Deletion, 72  
   Chromosome 18q, 860  
   Chromosome 22q11, 1544 (L)  
   Interstitial, 1184  
 Dementia, 948  
 Demographic history, 197  
 Denaturing gradient gel electrophoresis (DGGE), 1122, 1373  
 Dermal fibroblasts, 818  
 Dermo-epidermal junction, 1344  
 Development, 21, 869  
 Developmental disorders, 13 (E)  
 Developmental dyslexia, 27  
 Diabetes, 228 (L), 651, 1552 (L)  
   Type I, 174  
 Diagnostic criteria, 244 (L)  
 DiGeorge, 1194, 1544 (L)  
 Dihydropyridine receptor, 1316  
 Directiveness, 40  
 Discordant pairs, 1211  
 Discrimination, 205  
 Disease chromosomes, 1439  
 Disomy, 917  
 Distal arthrogyriposis, 426  
 DNA  
   Ancient, 1001 (L), 1002 (L)  
   Damage, 330  
   Instability, 879  
   Methylation, 574  
   Polymorphisms, 597  
   Pooling, 1461  
   Probes, 574  
   Repair, 320

- Sequencing, 1122
- Doctor-patient communication, 40
- Dominant inheritance, 540
- DRB1/DQB1 amino acid sites, 717
- Drug metabolism, 284
- Drug-metabolizing enzymes, 265 (E)
- Duarte variant, 366
- Duchenne muscular dystrophy, 160
  - Gene, 1555 (L)
- Duplication, 1363
  - CMT1A (Charcot-Marie-Tooth disease type 1A), 230 (L)
  - PKD1* gene, 1399
- Dutch populations, 1041
- Dynamic mutations, 460 (L)
- Dyskeratosis congenita, 581
- Dyslexia, 13 (E)
- Dystrophin transcripts, 1555 (L)
  
- Eclampsia, 1158
- Efficiency, 657
- Ehlers-Danlos syndrome
  - Type I, 547
  - Type II, 547
  - Type VI, 48
- Elastic microfibril, 1389
- Elderly, 948
- Encephalopathy, 1430
- Endopeptidase, 790
- Epidemiology, 667
- Epidermolysis bullosa, 352, 1344
- Epilepsy, 342, 667
- EPM1*, 342
- Ethnic-affiliation estimation, 957
- Ethnicity, 957
- European(s)
  - mtDNA variation, 1107
  - Origins, 1174
- Evolution, 1439
  - Human, 1174
  - Molecular, 772
- Exon skipping, 798, 1389
- Expanded trinucleotide repeat, 1548 (L)
- Expression, varied, 1079
- Expressivity, 10 (E)
- Extranuclear DNA, 1552 (L)
- Extraocular muscle, 1150
  
- Factor VIII, 565
- Familiality, 651
- Family history, 948
- FGFR3*, 555
- Fibrillin-2, 818, 1389
- Fibroblast growth factor receptor 3, 555
- Finnish populations, 1050, 1174
- FISH, 244 (L), 574, 1544 (L)
  - 5t alleles, 87
- Flies, 10 (E)
- FMR1*, 1354
- Folic acid, 229 (L), 433
- Footprinting, in vivo, 1354
- Forensic science, 957
- Fossil bone, 1002 (L)
- Founder effect, 103, 1068
- Founder mutation, 1041, 1059, 1079
- Fragile X syndrome, 103, 1354
- Frameshift, 565, 1122
- Frataxin gene, 460 (L)
- Freeman-Sheldon syndrome, 426
- French populations, 1021, 1236 (L)
- Friedreich ataxia, 460 (L), 1251 (L)
  
- Galactose-1-phosphate uridylyltransferase, 366
- Galactosemia, 366
- GALT (galactose-1-phosphate uridylyltransferase), 366
- GAP (GTPase-activating protein), 305
- Gene conversion, 808
- Gene dosage, 1411
- Gene expression, 638
- Gene mapping, 979, 1474
- Gene regulation, 278 (E)
- Gene tree, 772
- Genetic ancestry, 772
- Genetic counseling, 17 (E), 1003 (L)
- Genetic covariation, 143
- Genetic diagnosis, 1128
- Genetic instability, 460 (L)
- Genetic linkage, 1168
- Genetic predisposition, 910
- Genetic risk factor, 228 (L)
- Genetic testing, 205, 1085
- Genome scan(s), 657, 965, 979
- Genome screening, 459 (L)
- Genomic sequencing, 1354
- Genotype analysis, 851
- Genotype-phenotype correlation, 21
- Genotyping, 284
- Germ-line mutation, 1239 (L)
- Germ-line/somatic mosaicism, 1003 (L)
- Glaucoma, 272 (E), 296
- Glomus tumor, 121
- gooseoid*-like homeobox gene, 1194
- Gorlin syndrome, 10 (E)
- Growth
  - Failure, 896
  - Intrauterine, 997 (L)
  - Retardation, 917
- GTPase-activating protein, 305
  
- Hairpin, 879

- Haploinsufficiency, 547  
 Haplotype(s), 381, 1423  
   Method, 703, 717  
 Hearing impairment, nonsyndromic, 758 (R)  
*hedgehog*, 10 (E)  
 Helicase, 330  
 Hemidesmosome(s), 352, 1344  
 Hemochromatosis, 828, 1439  
 Hemoglobin genes, 755 (E)  
 Hemophilia A, 565  
 Hereditary hearing loss, 1168  
 Heritability, 143  
 Heterogeneity, 625, 758 (R), 1222, 1468  
   Genetic, 1542 (L)  
 Heterogeneous traits, 965  
 Heteroplasmy, 408, 1430  
 Heterozygosity, 1251 (L)  
 Heterozygote deficiency, 417  
 HLA, 174, 397, 738 (L)  
   Class II, 717  
 HLA-associated disease, 703, 717  
 HLA-H gene, 828  
 Homeobox, 1194  
 Homocysteine, 228 (L)  
 Homopolymer, 408  
 Homozygosity mapping, 1461  
 Human evolution, 755 (E)  
 Human origins, 772  
 Hungarian populations, 1242 (L)  
 Huntington disease, 879, 1202  
 Hybrid genes, 808  
 Hydroxylysine deficiency, 48  
 Hydroxymethylbilane synthase, 1373  
 Hyperhomocysteinemia, 999 (L)  
 Hypermethioninemia, 540  
 Hyperostosis, 1309 (E)  
 Hypertension, 188, 732 (L), 1448  
 Hypoparathyroidism, 153  
 Hypophosphatemia, 790
- Iceland, 1079  
 Identity by descent, 979  
 Imprinting, 121, 574, 928  
 In vivo footprinting, 1354  
 Inbreeding, 965  
 Inherited cataract, 1474  
 Insulin-dependent diabetes mellitus, 703  
   Predisposition, 717  
 Insulin-receptor gene, 1532 (L)  
 Insulin-resistance syndrome, 143  
 Insulin-severity index, 1532 (L)  
 Insurability, 205  
 Insurance, 205  
 Interstitial deletion, 1184  
 Intraallelic variability, 447
- Intrauterine growth retardation, 917  
 Inversion  
   Chromosomal, 1184  
   Paracentric, 1184  
   Pericentric, 574  
 Iron overload, 828  
 Italian populations, 828
- Japanese, 565, 732 (L)  
 Juvenile retinoschisis, 1139
- Kidney, 790
- L-type voltage-dependent calcium channel, 1316  
 Late replication, 1558 (L)  
 Leber hereditary optic neuropathy, 381, 1539 (L)  
 Leigh syndrome, 1495  
 LGMD1B (limb-girdle muscular dystrophy 1B), 891  
 LGMD2A (limb-girdle muscular dystrophy 2A), 1128  
 LHON (Leber hereditary optic neuropathy), 381,  
   1539 (L)  
   Mutations, 1107  
 Library, 463 (L)  
 Libyan Jews, 617  
 Lifetime risks, 439  
 Likelihoods, 657  
 Limb-girdle muscular dystrophy, 891, 1128  
 Linkage, 27, 133, 166, 296, 588, 625, 657, 740 (L),  
   896, 979, 1461  
   Analysis, 121, 217, 581, 597, 605, 611, 735 (L), 738  
   (L), 965, 1158, 1211, 1468, 1479  
   Disequilibrium, 188, 397, 617, 896, 1139, 1439,  
   1461, 1479, 1513, 1548 (L)  
   Mapping, 459 (L)  
 Linker, 463 (L)  
 Lipids, 638  
 Lipoproteins, 638, 1502  
 LOD score(s), 133, 735 (L), 738 (L)  
 Los Angeles variant, 366  
 Loss of heterozygosity, 80  
 Lowe oculocerebrorenal syndrome, 1384  
 Lysinuric protein intolerance (LPI), 1479  
 Lysyl hydroxylase, 48
- Machado-Joseph disease, 993 (L), 1548 (L)  
 Major histocompatibility complex, 174, 397  
 Male breast cancer, 313  
 Male infertility, 237 (L)  
 Malformations, 474  
 Malignancies, 469 (E)  
 Malignant hyperthermia, 833, 1303 (E), 1316  
 Manganese superoxide dismutase, 588  
 Mapping, 1222  
   Chromosome 6, 174  
   Fine-scale, 1513

- Genetic, 965
- Marfan syndrome, 1389
- Markers, 459 (L)
- Maternal-fetal exchange, 738 (L)
- Maternal-fetal interaction, 1006 (L)
- Medical economics, 244 (L)
- Megaloblastic anemia, 525
- Meiotic drive, 1562 (L)
- MEN 2A (multiple endocrine neoplasia type 2A), 233 (L)
- MEN 2B (multiple endocrine neoplasia type 2B), 233 (L)
- Menkes disease, 63
- Mental illness, 630
- Mental retardation, 113, 903
- Metabolic cardiovascular syndrome, 143
- Metabolism, 1552 (L)
- Methionine adenosyltransferase deficiency, 540
- Method of mod scores, 217
- Methylation, 244 (L), 751 (E), 1354, 1558 (L)
  - Blot, 928
- Methylenetetrahydrofolate reductase (MTHFR), 228 (L), 229 (L), 1006 (L)
- MHC (major histocompatibility complex), 174, 397
- Microcell-mediated chromosome transfer, 1487
- Microcephaly, 997 (L)
- Microsatellite(s), 459 (L), 928, 1174
  - Instability, 910
  - Markers, 611
- Midfrequency deafness, 1168
- Migrants, 188
- Migrations, Native American, 241 (L)
- Minibrain gene, 997 (L)
- Minisatellite DNA, 417
- Miscarriage, 738 (L)
- Missense, 1122
  - Mutation, 1251 (L)
- Mitochondria, 373, 408, 1363
- Mitochondrial transcription-factor A, 1363
- MMLS (method of mod scores), 217
- MNK*, 63
- MnSOD (manganese superoxide dismutase), 588
- Mod score(s), 217
- Molecular evolution, 772
- Monosomy 21, 997 (L)
- Monte Carlo integration, 447
- Mood disorders, 1283 (E)
- Mosaicism, 818, 993 (L)
- mRNA editing, 278 (E), 305
- MRX* genes, 903
- mtDNA, 153, 373, 381, 408, 755 (E), 999 (L), 1002 (L), 1107, 1363, 1430, 1495, 1539 (L), 1552 (E)
  - Haplogroups, 1539 (L)
  - Haplotypes, 1107
  - Variation, 241 (L)
- MTHFR (methylenetetrahydrofolate reductase), 228 (L), 229 (L), 1006 (L)
- Mulibrey nanism, 896
- Multiple alleles, 691
- Multiple comparisons, 1532 (L)
- Multiple endocrine neoplasia, 233 (L)
- Multiple exostoses, 80
- Multiple loci, 1222
- Multiple tests, 217
- Multipoint analysis, 1326
- Muscle biopsy, 1542 (L)
- Muscle-specific calpain, 1128
- Mutation(s), 486, 1128, 1423
  - Analysis, 57, 515, 828, 1068
  - BRCA1*, 1050
  - Breast cancer, 313
  - cystatin B*, 342
  - De novo, 233 (L)
  - Detection, 63, 1411, 1542 (L)
  - Dynamic, 993 (L)
  - FBN2*, 818
  - Founder, 505
  - Germ line, 1233 (L)
  - Hypermethioninemia, 540
  - Hot spot, 869
  - Hereditary multiple exostoses, 80
  - Leber hereditary optic neuropathy, 381
  - Missense, 1122, 1251
  - mtDNA, 1495
  - Nonsense, 729 (L), 1122
  - PKD1* gene, 1399
  - Porphyria, 1373
  - SCA3/MJD (spinocerebellar ataxia type 3/Machado-Joseph disease), 1548 (L)
  - Screening, 869
  - Von Hippel-Lindau disease, 765
- Mutifunctional protein, 525
- Myocardial infarction, 999 (L)
- Myoclonus epilepsy, Unverricht-Lundborg, 342
- Myopathy, 373, 1363
- Myotonic dystrophy, 1562 (L)
- Myotubular myopathy, 1542 (L)
- Nail-patella syndrome, 133
- Narcolepsy, 1289 (E)
- Native Americans, 241 (L)
- NBCCS (nevroid basal cell carcinoma syndrome), 21
- Neoplasia, 469 (E)
- Neural tube defects, 229 (L), 433, 1006 (L)
- Neuroblastoma, 1256 (L)
- Neurodegenerative disorder, 842
- Neurofibromatosis, 305
- Nevroid basal cell carcinoma syndrome, 21
- NIDDM (non-insulin-dependent diabetes mellitus), 188, 228 (L), 651, 1532 (L)

- Nijmegen breakage syndrome, 605, 1246 (L), 1487  
 Nondirectiveness, 40  
 Non-insulin-dependent diabetes, 188, 288 (L), 651, 1532 (L)  
 Nonisotopic RNase cleavage assay, 1399  
 Non-Jewish, 1099  
 Nonsense, 1122  
   Mutation, 729 (L)  
 Nonsyndromic hearing loss, 1168  
 Nucleotide excision repair, 320
- Obesity, 143, 166, 188  
*OCRL1* gene, 1384  
 Oculocerebrorenal syndrome, Lowe, 1384  
 Odds ratios, 439  
 Ojibwa, 241 (L)  
 185delAG mutation, 1085  
 Onset, 630  
 Onychoosteodysplasia, 133  
 Oocytes, 408, 1495  
 Optic neuropathy, 272 (E)  
 Orotic aciduria, hereditary, 525  
 Osseous tissue, 1309 (E)  
 Osteoporosis, 1309 (E)  
 Osteosclerosis, 1309 (E)  
 Ovarian cancer, 496, 505, 1021, 1041, 1068, 1085, 1233 (L), 1239 (L), 1242 (L)  
 Oxidative stress, 228 (L)
- p44, 72  
 PAH mutations, 95  
 Panhypopituitarism, 910  
 Paracentric inversion, 1184  
 Paraganglioma, 121  
 Parental gender, 460 (L)  
 Parental origin, 230 (L), 233 (L)  
 Parkinson disease, 588  
 Parkinsonism, 588  
*patched* mutation, 10 (E)  
*PATCHED* (*PTCH*, human homologue of *Drosophila patched* gene), 21  
*PAX2*, 869  
 PCR, 935  
 Pedigree analysis, 1326  
 Penetrance, partial, 87  
 Peroxisomal biogenesis defect, 1535 (L)  
 Peroxisomes, 1535 (L)  
*PEX* gene, 790  
 Pharmacogenetics, 265 (E), 284  
 Pharmacokinetics, 284  
 Phenotypic mapping, 860  
 Phenotypic variation, 869  
 Phenylalanine hydroxylase, 388  
 Phenylketonuria, 95, 388  
 Pheochromocytoma, 765
- Phosphatidylinositols, 1384  
 Phosphoinositides, 1384  
 Phylogenetic analysis, 1107  
 Phylogenetic estimation, 755 (E)  
 Physical mapping, 1139  
 Pima Indians, 166, 651  
*PKD1*, 1399  
 PKU (phenylketonuria), 95, 388  
 Placental mosaicism, 917  
 Point mutation(s), 63, 555  
 Polycystic kidney disease, 1399  
 Polygenic disease, 381  
 Polygenic trait, 1552 (L)  
 Polymorphism, 1532 (L)  
   Base substitution, 1174  
 Polypyrimidine tract, 1389  
 Population(s), 197, 447, 1013 (E), 1532 (L)  
   Aboriginal, 1552 (L)  
   African, 755 (E)  
   African American, 1233 (L)  
   Ashkenazi, 505, 1085  
   Asian, 676, 755, 1174  
   British, 388, 474  
   Centenarian, 999 (L)  
   Danish, 1532 (L)  
   European, 1107, 1174  
   Finnish, 1050, 1174  
   French, 1021, 1236 (L)  
   Genetics, 1174, 1513  
   Hungarian, 1242 (L)  
   Icelandic, 1079  
   Italian, 828  
   Japanese, 565, 732 (L)  
   Jewish, 1059  
   Native American, 241 (L)  
   Ojibwa, 241 (L)  
   Russian, 1239 (L)  
   Scandinavian, 1068  
   Screening, 935  
 Population-based genetic testing, 1085  
 Population-specific alleles, 957  
 Porphobilinogen deaminase gene, 1373  
 Porphyria, 1373  
 Postaxial polydactyly type A, 597  
 Power, 657  
 Prader-Willi syndrome, 244 (L)  
 Pre-mRNA, 729 (L)  
 Predisposing amino acids, 703  
 Preeclampsia, 1158  
 Pregnant populations, 935  
 Premature termination codon, 729 (L)  
 Primary open-angle glaucoma, 296  
 Probability, 1202  
 Progeria, 330  
 Promoter, 1354

- Protein-truncation test, 1399  
Psychiatric disorder(s), 851, 1276 (E)  
Ptosis, 1150
- Quantitative trait(s), 676, 740 (L), 1326  
  Loci, 676, 1211  
  PCR, 1411
- Race, 957  
Racial subpopulations, 229 (L)  
Radiosensitivity, 605  
Rapid-expansion detection, 730 (L)  
*RB1* gene, 1558 (L)  
Reading disability, 27  
Recombination, 397  
  Hot spot, 808  
  Opportunities, 197  
Red blood cells, 433  
RED (rapid-expansion detection), 730 (L)  
Refsum disease, infantile, 1535 (L)  
Renal cell carcinomas, 751 (E), 765  
Renal-coloboma syndrome, 869  
Restriction mapping, 1139  
*RET*, 233 (L)  
Retinal disease, 1468  
Retinoblastoma, 1558 (L)  
Retinoschisis, juvenile, 1139  
Reverse-transcriptase PCR, 1555 (L)  
RFLP haplotypes, 95  
RH blood group, 808  
RH variants, 808  
Rheumatoid arthritis, 703, 738 (L)  
Rickets, 790  
Risk assessment, 910  
RNA  
  Levels, 87  
  Processing, 305, 798  
  Stability, 729 (L)  
RNA-binding protein, 237 (L)  
RNA-SSCP, 828  
Russian populations, 1239 (L)  
Ryanodine receptor gene, 833  
*RYR1* gene, 833
- Sampling, 1222  
Sarcoglycans, 891  
SCA2 (spinocerebellar ataxia type 2), 842  
Scandinavian population, 1068  
Schizophrenia, 630  
Screening, 459 (L)  
  Breast and ovarian cancer, 1085  
  Genetic, 1099  
Segregation, 1430, 1495  
  Analysis, 667  
Seizures, 667
- Sequence, 463 (L)  
  Variation, 388  
Sequencing, 1539 (L)  
70-kD peroxisomal membrane protein, 1535 (L)  
Short alleles, 417  
Short tandem repeat, 95  
  Polymorphism, 459 (L)  
Sib-pair analysis, 1211  
Sibling pair(s), 740 (L), 965  
Significance levels, 217  
Simulation(s), 217, 625  
Single-minded gene, 997 (L)  
617delT mutation, 1085  
Skeletal mass, 1309 (E)  
Skeletal muscle, 373, 1316  
*SLC3A1*, 617  
Sleep disorders, 1289 (E)  
Smith-Magenis syndrome, 1184  
Somatic-cell fusion, 1487  
Somatic-cell hybrids, 860, 1333  
Sorsby fundus dystrophy, 57  
Spastic paraplegia, 625  
Spatial patterns, 388  
Spermatogonia, 237 (L)  
Spinal DXA, 1326  
Spinal muscular atrophy, 72  
Spinal muscular dystrophy, 1411  
Spinocerebellar ataxias, 993 (L)  
  Type 2, 842  
  Type 3, 1548 (L)  
Splice, 818  
  Site, 1122  
Splicing, 729 (L)  
  Defects, 547  
SSCP, 63, 1539 (L)  
Statistical power, 676  
Stop-codon polymorphism, 1548 (L)  
STR (short tandem repeat), 95  
Strategy, 657  
Surgery, 1303 (E)  
Survival  
  Analysis, 1202  
  Variant alleles, 197  
Survival motor neuron gene, 72  
Susceptibility, 486  
  Gene(s), 1068, 1158  
Syndromes, congenital, 469 (E)
- Tay-Sachs disease, 1099  
TDT (transmission-disequilibrium test), 188, 191, 676,  
  691, 1006  
Telomere healing, 113  
Terminal microdeletion, 113  
Thyroid carcinoma, 233 (L)  
TIMP3 (tissue inhibitor of metalloproteinase-3), 57

- Tissue inhibitor of metalloproteinase-3, 57  
Transcription, 1423  
  Control, 1333  
  Factor TFIID, 72, 320  
  Syndromes, 320  
Translocation, 1558 (L)  
Transmission-disequilibrium test(s), 188, 191, 676, 691,  
  1006 (L)  
Treacher Collins syndrome, 515  
Trichothiodystrophy, 320  
Triglyceride, 1502  
Trinucleotide repeat, 879  
Triplasm, 1430  
Triplet repeat(s), 730 (L), 1251 (L)  
  Instability, 103  
Trisomy, 917  
tRNA mutation, 373  
Truncating mutations, 21  
Tumor suppressor, 305  
  Gene, 21  
Tumorigenesis, 305, 751 (E), 765  
Tunisian Jew, 103  
Turkish family, 732 (L)  
Twin(s), 143, 433, 638  
  Studies, 1502  
Type 1 diabetes, 174  
UMP (uridine monophosphate) synthase, 525  
Uniparental disomy, 160, 917  
Unipolar disorders, 730 (L)  
Unverricht-Lundborg, myoclonus epilepsy, 342  
Uridine monophosphate synthase, 525  
Urofacial syndrome, 1461  
Variant alleles, 197  
VCFS (velo-cardio-facial syndrome), 851, 1194  
Velo-cardio-facial syndrome, 851, 1194  
Ventricular-septal heart defect, 1544 (L)  
Visual defects, 272 (E)  
Vitamins, 433  
VNTR, 95  
Von Hippel-Lindau disease/syndrome, 751 (L), 765  
Werdnig-Hoffman disease, 72  
Werner syndrome, 330  
Wilson disease, 1423  
Xeroderma pigmentosum, 320  
YAC contig, 860  
Zellweger syndrome, 1535 (L)